Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 24, 2025 11:32 ET | Source: Research and Markets

Diabetic Neuropathic Pain Analysis Report 2025: Global Market Set for Growth, Reaching $8.5 Billion by 2032 Featuring Pfizer, NeuroMetrix, GSK, Johnson & Johnson, and Lupin

Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Diabetic Neuropathic Pain Market" report has been added to ResearchAndMarkets.com's offering. Diabetic neuropathic pain market is projected to...
July 01, 2024 07:38 ET | Source: Research and Markets

Diabetic Neuropathic Pain Treatment Landscape 2024: Comprehensive Insights About 10+ Companies and 12+ Pipeline Drugs - Product Type, Stage, Route of Administration, and Molecule Type

Dublin, July 01, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Neuropathic Pain - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Diabetic Neuropathic...
May 04, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Diabetic Neuropathic Pain Market to Proliferate, Assesses DelveInsight | Key Companies Active in the Domain - AstraZeneca, Eli Lilly and Company, Eisai, Helixmith, Lexicon, NeurogesX, Centrexion, Pure Green Pharmaceuticals

New York, USA, May 04, 2023 (GLOBE NEWSWIRE) -- Diabetic Neuropathic Pain Market to Proliferate, Assesses DelveInsight | Key Companies Active in the Domain - AstraZeneca, Eli Lilly and Company,...
August 12, 2021 07:00 ET | Source: Trevena Inc.

Trevena Reports Second Quarter 2021 Results

Company reaffirms YE goal of 100 formulary wins OLINVYK respiratory physiology study currently enrolling, topline data expected by YE 2021 NIH / Vanderbilt University Medical Center-led...
May 06, 2021 07:00 ET | Source: Trevena Inc.

Trevena Reports First Quarter 2021 Results

-- Company reaffirms YE target of 100 formulary approvals for OLINVYK® Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and...